Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Masato Furuhashi, Gürol Tuncman, Cem Z. Görgün, Liza Makowski, Genichi Atsumi, Eric Vaillancourt, Keita Kono, Vladimir R. Babaev, Sergio Fazio, MacRae F. Linton, Richard Sulsky, Jeffrey A. Robl, Rex A. Parker, Gökhan S. Hotamisligil

Research output: Contribution to journalArticle

442 Citations (Scopus)

Abstract

Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages, and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice have shown that this lipid chaperone has a significant role in several aspects of metabolic syndrome, including type 2 diabetes and atherosclerosis. Here we demonstrate that an orally active small-molecule inhibitor of aP2 is an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse models. In macrophage and adipocyte cell lines with or without aP2, we also show the target specificity of this chemical intervention and its mechanisms of action on metabolic and inflammatory pathways. Our findings demonstrate that targeting aP2 with small-molecule inhibitors is possible and can lead to a new class of powerful therapeutic agents to prevent and treat metabolic diseases such as type 2 diabetes and atherosclerosis.

Original languageEnglish (US)
Pages (from-to)959-965
Number of pages7
JournalNature
Volume447
Issue number7147
DOIs
StatePublished - Jun 21 2007
Externally publishedYes

Fingerprint

Fatty Acid-Binding Proteins
Adipocytes
Type 2 Diabetes Mellitus
Atherosclerosis
Macrophages
Metabolic Diseases
Metabolic Networks and Pathways
Therapeutics
Lipids
Cell Line

ASJC Scopus subject areas

  • General

Cite this

Furuhashi, M., Tuncman, G., Görgün, C. Z., Makowski, L., Atsumi, G., Vaillancourt, E., ... Hotamisligil, G. S. (2007). Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature, 447(7147), 959-965. https://doi.org/10.1038/nature05844

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. / Furuhashi, Masato; Tuncman, Gürol; Görgün, Cem Z.; Makowski, Liza; Atsumi, Genichi; Vaillancourt, Eric; Kono, Keita; Babaev, Vladimir R.; Fazio, Sergio; Linton, MacRae F.; Sulsky, Richard; Robl, Jeffrey A.; Parker, Rex A.; Hotamisligil, Gökhan S.

In: Nature, Vol. 447, No. 7147, 21.06.2007, p. 959-965.

Research output: Contribution to journalArticle

Furuhashi, M, Tuncman, G, Görgün, CZ, Makowski, L, Atsumi, G, Vaillancourt, E, Kono, K, Babaev, VR, Fazio, S, Linton, MF, Sulsky, R, Robl, JA, Parker, RA & Hotamisligil, GS 2007, 'Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2', Nature, vol. 447, no. 7147, pp. 959-965. https://doi.org/10.1038/nature05844
Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007 Jun 21;447(7147):959-965. https://doi.org/10.1038/nature05844
Furuhashi, Masato ; Tuncman, Gürol ; Görgün, Cem Z. ; Makowski, Liza ; Atsumi, Genichi ; Vaillancourt, Eric ; Kono, Keita ; Babaev, Vladimir R. ; Fazio, Sergio ; Linton, MacRae F. ; Sulsky, Richard ; Robl, Jeffrey A. ; Parker, Rex A. ; Hotamisligil, Gökhan S. / Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. In: Nature. 2007 ; Vol. 447, No. 7147. pp. 959-965.
@article{29509cf9542847c3bb45a55124275b43,
title = "Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2",
abstract = "Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages, and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice have shown that this lipid chaperone has a significant role in several aspects of metabolic syndrome, including type 2 diabetes and atherosclerosis. Here we demonstrate that an orally active small-molecule inhibitor of aP2 is an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse models. In macrophage and adipocyte cell lines with or without aP2, we also show the target specificity of this chemical intervention and its mechanisms of action on metabolic and inflammatory pathways. Our findings demonstrate that targeting aP2 with small-molecule inhibitors is possible and can lead to a new class of powerful therapeutic agents to prevent and treat metabolic diseases such as type 2 diabetes and atherosclerosis.",
author = "Masato Furuhashi and G{\"u}rol Tuncman and G{\"o}rg{\"u}n, {Cem Z.} and Liza Makowski and Genichi Atsumi and Eric Vaillancourt and Keita Kono and Babaev, {Vladimir R.} and Sergio Fazio and Linton, {MacRae F.} and Richard Sulsky and Robl, {Jeffrey A.} and Parker, {Rex A.} and Hotamisligil, {G{\"o}khan S.}",
year = "2007",
month = "6",
day = "21",
doi = "10.1038/nature05844",
language = "English (US)",
volume = "447",
pages = "959--965",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7147",

}

TY - JOUR

T1 - Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

AU - Furuhashi, Masato

AU - Tuncman, Gürol

AU - Görgün, Cem Z.

AU - Makowski, Liza

AU - Atsumi, Genichi

AU - Vaillancourt, Eric

AU - Kono, Keita

AU - Babaev, Vladimir R.

AU - Fazio, Sergio

AU - Linton, MacRae F.

AU - Sulsky, Richard

AU - Robl, Jeffrey A.

AU - Parker, Rex A.

AU - Hotamisligil, Gökhan S.

PY - 2007/6/21

Y1 - 2007/6/21

N2 - Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages, and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice have shown that this lipid chaperone has a significant role in several aspects of metabolic syndrome, including type 2 diabetes and atherosclerosis. Here we demonstrate that an orally active small-molecule inhibitor of aP2 is an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse models. In macrophage and adipocyte cell lines with or without aP2, we also show the target specificity of this chemical intervention and its mechanisms of action on metabolic and inflammatory pathways. Our findings demonstrate that targeting aP2 with small-molecule inhibitors is possible and can lead to a new class of powerful therapeutic agents to prevent and treat metabolic diseases such as type 2 diabetes and atherosclerosis.

AB - Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages, and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice have shown that this lipid chaperone has a significant role in several aspects of metabolic syndrome, including type 2 diabetes and atherosclerosis. Here we demonstrate that an orally active small-molecule inhibitor of aP2 is an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse models. In macrophage and adipocyte cell lines with or without aP2, we also show the target specificity of this chemical intervention and its mechanisms of action on metabolic and inflammatory pathways. Our findings demonstrate that targeting aP2 with small-molecule inhibitors is possible and can lead to a new class of powerful therapeutic agents to prevent and treat metabolic diseases such as type 2 diabetes and atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=34250904186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250904186&partnerID=8YFLogxK

U2 - 10.1038/nature05844

DO - 10.1038/nature05844

M3 - Article

C2 - 17554340

AN - SCOPUS:34250904186

VL - 447

SP - 959

EP - 965

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7147

ER -